Mechanisms of action of antidepressants: New data from Escitalopram;De nouvelles données pour appréhender les mécanismes d'action des antidépresseurs: L'apport du Escitalopram

Encephale

Volumn 29, Issue 3 I, 2003, Pages 259-265

  Fabre, V ^a   Hamon, M ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Early onset of antidepressant action; Escitalopram; Selectivity; Sigma ( ) receptors; SSRI

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; HISTAMINE H1 RECEPTOR; IMIPRAMINE; MUSCARINIC RECEPTOR; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIGMA OPIATE RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; DEPRESSION; DRUG SELECTIVITY; FORCED SWIMMING TEST; HUMAN; NEUROTRANSMISSION; ORTHOSTATIC HYPOTENSION; SIDE EFFECT; TREATMENT FAILURE; VOCALIZATION; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; CITALOPRAM; FRONTAL LOBE; HUMANS; HYPOTENSION, ORTHOSTATIC; LOCOMOTION; RATS; RECEPTORS, DOPAMINE; RECEPTORS, SIGMA; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SODIUM CHLORIDE; TACHYCARDIA; VOCALIZATION, ANIMAL;

EID: 0038110850     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. AKUNNE HC, ZOSKI KT, WHETZEL SZ et al. Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant. Neuropharmacology 2001; 41: 138-49.
2. ANDERSON IM, TOMENSON BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a metaanalysis. Br Med J 1995; 310: 1433-8.
3. BAUMANN P, ZULLINO DF, EAP CB. Enantiomers' potential in psychopharmacology - a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 2002; 12: 433-44.
4. BERMACK JE, DEBONNEL G. Modulation of serotonergic neurotransmission by short - and long-term treatments with sigma ligands. Br J Pharmacol 2001; 134: 691-9.
5. BURKE WJ. Escitalopram. Expert Opin Investig Drugs 2002; 11: 1477-86.
6. BURKE WJ, GERGEL I, BOSE A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 4.
7. CRYAN JF, MARKOU A, LUCKI I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002; 23: 238-45.
8. GORMAN JM, KOROTZER A, SU G. Efficacy comparison of escitalopram and citalopram in the treatement of major depressive discorder: pooled analysis of placebo-controlled trials. CNS Spectrums - Academic Supplements. Ing J Neuropsychiatric Medicine 2002; 7 (Suppl 1): 40-4.
9. 1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn-Schmiedeberg's Arch Pharmacol 1995; 352: 141-8.
10. 1) receptor function: Behavioural consequences and therapeutic opportunities. Brain Res Rev 2001; 37: 116-32.
11. MONTGOMERY SA, LOFT H, SANCHEZ C et al. Escitalopram (Senantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 2001; 88: 282-6.
12. MØRK A, KREILGAARD M, SANCHEZ C. Escitalopram: A comparative study of in vitro and in vivo 5-HT uptake inhibitory activity. XXIII CINP Congress, Montreal, June 23-27, 2002.
13. NARITA N, HASHIMOTO K, TOMIKATA SI et al. Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain. Eur J Pharmacol 1996; 307: 117-9.
14. OWENS MJ, KNIGHT DL, NEMEROFF CB. Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry 2000; 47: 842-5.
15. OWENS JM, KNIGHT DL, NEMEROFF CB. Inhibiteurs spécifiques de la recapture de la sérotonine (ISRS) de deuxième génération: profil de liaison du transporteur de l'escitalopram et de la R-fluoxétine chez l'homme. Encephale 2002; XXVIII: 350-5.
16. OWENS MJ, MORGAN WN, PLOTT SJ et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283: 1305-22.
17. PINEYRO G, BLIER P. Autoregulation of serotonin neurons: Role in antidepressant drug action. Pharmacol Rev 1999; 51: 533-91.
18. PORSOLT RD, LE PICHON M, JALFRE M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266: 730-2.
19. QUIRION R, CHICHEPORTICHE R, CONTRERAS PC et al. Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci 1987; 10: 444-6.
20. RICHELSON E, NELSON A. Antagonism by antidepressants of neurotransmitter receptors of nomal human brain in vitro. J Pharmacol Exp Ther 1984; 230: 94-102.
21. SANCHEZ C. Escitalopram has potent effects in animal models of anxiety and depression. XXIII CINP Congress, Montreal, June 23-27, 2002.
22. SANCHEZ C. Stress-induced vocalisation in adult animals. A valid model of anxiety? Eur J Pharmacol. 2003; 463: 133-43.
23. SANCHEZ C. R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur J Pharmacol 2003; 464: 155-8.
24. 2-ligand Lu 28-179 has potent anxiolytic-like effects in rodents. J Pharmacol Exp Ther 1997; 283: 1323-32.
25. SANCHEZ C, HYTTEL J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999; 19: 467-89.
26. SANCHEZ C, PAPP M. The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behav Pharmacol 2000; 11: 117-24.
27. SPADONE C. Effets du Escitalopram sur les symptômes anxieux de la dépression. Encephale 2002; XXVIII: 461-5.
28. UKAI M, MAEDA H, NANYA Y et al. Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol Biochem Behav 1998; 61: 247-52.
29. 1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001; 298: 1269-79.
30. WADE A, LEMMING OM, HEDEGAARD KB. Escitalopram 10 mg/ day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95-102.
31. WILLNER P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl.) 1997; 134: 319-29.